Resources

This report describes the evidence and policy needs of global and country decision-makers, public health program planners, and implementers that may be involved in maternal respiratory syncytial virus (RSV) vaccine decisions or delivery. The report focuses specifically on the context of potential introduction in low- and middle-income countries (LMICs) and summarizes relevant evidence across the following broad topic areas: 1) disease, 2) product, 3) health economics and financing, and 4) vaccine service delivery. Critical gaps in evidence are highlighted that, if left unfilled, could delay or preclude vaccine introduction in LMICs.Advancing Maternal Immunization (AMI) is a collaboration of cross-sectoral experts convened by PATH and WHO with the purpose of advancing RSV MI.

Ce guide aide les personnes commises au plaidoyer (les influenceurs) et les DÉCIDEURS à comprendre la nécessité d'accroître l'accès à l'oxygène et la façon de le faire, même dans des contextes où les ressources sont limitées. Il fournit des données, des messages et des ressources pouvant aider à comprendre la planification, les politiques et les technologies impliquées dans la mise à l'échelle de la distribution d'oxygène. Cet outil est utile à quiconque souhaite en savoir plus sur l'augmentation de l'accès à l'oxygène et l'intégration de la distribution d'oxygène dans les politiques, les programmes et les budgets de santé nationaux et infranationaux. L’abécédaire n’est pas marqué et reste personnalisable, ce qui permet aux défenseurs et aux décideurs d'utiliser ces ressources de la façon qui convient le mieux à leurs besoins.Version anglaise disponible ici: https://www.path.org/resources/oxygen-is-essential-a-policy-and-advocacy-primer/

PATH is implementing a comprehensive approach to increase access to oxygen in low- and middle-income countries, including supporting normative policy change by the World Health Organization (WHO), helping strengthen markets for oxygen concentrators and pulse oximeters, raising awareness about the importance of oxygen through its HO2PE: Oxygen Gives Life campaign, partnering with the United for Oxygen alliance, and developing a suite of evidence-based materials to help advocates and policymakers drive change at the national level.

Subcutaneous DMPA (DMPA-SC, brand name Sayana® Press) is a new, easy-to-use injectable contraceptive that is ideally suited for remote access and even self-injection. This research brief describes new research findings that women who self-injection DMPA-SC continue to use contraception longer than women who use intramuscular DMPA (DMPA-IM, brand name Depo-Provera®) administered by a health worker. For more information, visit www.path.org/dmpa-sc or email FPoptions@path.org.

There is broad recognition of the growing and inequitable burden of cervical cancer in low-resource countries, and uptake of new screening and treatment alternatives for adult women and human papillomavirus (HPV) vaccines for young adolescent girls is on the rise. For the first time in history the elimination of the disease is within reach, and on May 19, 2018, WHO Director-General, Dr. Tedros Adhanom Ghebreyesus made a global call for action on cervical cancer elimination. This fact sheet summarizes PATH's current work and future priorities.